Prolixin Decanoate
Generic name:fluphenazine decanoate
Dosage form: Injection, USP
Drug class:Phenothiazine antipsychotics
Medically reviewed by Drugs.com. Last updated on Jul 22, 2021.
On This Page
The Prolixin Decanoate brand name has been discontinued in the U.S. If generic versions of this product have been approved by the FDA, there may be generic equivalents available.
Prolixin Decanoate Description
Prolixin Decanoate is the decanoate ester of a trifluoromethyl phenothiazine derivative. It is a highly potent behavior modifier with a markedly extended duration of effect. Prolixin Decanoate is available for intramuscular or subcutaneous administration, providing 25 mg fluphenazine decanoate per mL in a sesame oil vehicle with 1.2% (w/v) benzyl alcohol as a preservative. At the time of manufacture, the air in the vials is replaced by nitrogen.
Prolixin Decanoate - Clinical Pharmacology
The basic effects of fluphenazine decanoate appear to be no different from those of fluphenazine hydrochloride, with the exception of duration of action. The esterification of fluphenazine markedly prolongs the drug’s duration of effect without unduly attenuating its beneficial action.
Prolixin Decanoate has activity at all levels of the central nervous system as well as on multiple organ systems. The mechanism whereby its therapeutic action is exerted is unknown.
Fluphenazine differs from other phenothiazine derivatives in several respects: it is more potent on a milligram basis, it has less potentiating effect on central nervous system depressants and anesthetics than do some of the phenothiazines and appears to be less sedating, and it is less likely than some of the older phenothiazines to produce hypotension (nevertheless, appropriate cautions should be observed—see sections on PRECAUTIONS and ADVERSE REACTIONS).
Indications and Usage for Prolixin Decanoate
Prolixin Decanoate (Fluphenazine Decanoate Injection) is a long-acting parenteral antipsychotic drug intended for use in the management of patients requiring prolonged parenteral neuroleptic therapy (e.g., chronic schizophrenics).
Prolixin Decanoate has not been shown effective in the management of behavioral complications in patients with mental retardation.
